Impact of Short-course Colchicine Versus Placebo After Pulmonary Vein Isolation (IMPROVE-PVI Pilot)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 202 participants.

Also called NCT04160117

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 202 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04160117
Other papers using this trial's data
  • Colchicine to Prevent Atrial Fibrillation Recurrence After Catheter Ablation: A Randomized, Placebo-Controlled Trial Circulation. Arrhythmia and electrophysiology, 2024-01 DOI, PubMed 38126206

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Canada (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04160117. Randomized; quadruple masking; primary purpose treatment. Start 2020-01-14 (actual); primary completion 2022-05-30 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Impact of Short-course Colchicine Versus Placebo After Pulmonary Vein Isolation (IMPROVE-PVI Pilot)
Condition
Recurrence
Intervention (Drug)
Colchicine 0.6 mg
Intervention (Drug)
Matching placebo
Lead sponsor
Population Health Research Institute (class: other)

Record details

Record id
cardio:ct-nct04160117
Content hash
a927e694431d32dcec3263736e24df6db768c8c7a31d61051963a97e9ef3dac8